Targeting non-alcoholic fatty liver disease: Design, X-ray co-crystal structure and synthesis of 'first-in-kind' inhibitors of serine/threonine kinase25

Bioorg Med Chem Lett. 2022 Nov 1:75:128950. doi: 10.1016/j.bmcl.2022.128950. Epub 2022 Aug 24.

Abstract

We describe the synthesis of a series of 3-t-butyl 5-aminopyrazole p-substituted arylamides as inhibitors of serine-threonine25 (STK25), an enzyme implicated in the progression of non-alcoholic fatty liver disease (NAFLD). Appending a p-N-pyrrolidinosulphonamide group to the arylamide group led to a 'first-in kind' inhibitor with IC50 = 228 nM. A co-crystal structure with STK 25 revealed productive interactions which were also reproduced using molecular docking. A new series of triazolo dihydro oxazine carboxamides of 3-t-butyl 5-aminopyrazole was not active against STK25.

Keywords: Aminopyrazole; Enzyme inhibitor; Structure-based design; Sulphonamide.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Humans
  • Intracellular Signaling Peptides and Proteins
  • Molecular Docking Simulation
  • Non-alcoholic Fatty Liver Disease* / drug therapy
  • Oxazines
  • Protein Serine-Threonine Kinases
  • Serine
  • Threonine
  • X-Rays

Substances

  • Intracellular Signaling Peptides and Proteins
  • Oxazines
  • Threonine
  • Serine
  • Protein Serine-Threonine Kinases
  • STK25 protein, human